"Positive Zotatifin Data Supports An Opportunity In Breast Cancer" - Cantor Fitzgerald Bullish on eFFECTOR Therapeutics (EFTR) With Overweight Rating, $50 Price Target
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $50.00 price target on eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE